The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
University of Southern California, USC Schaeffer Center, 635 Downey Way, Los Angeles, CA 90089-3333. E-mail: [email protected]
- Published Article
The American journal of managed care
- Publication Date
Oct 01, 2017
Option value is important when valuing therapies like nivolumab that extend life in a rapidly evolving area of care.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/29087638